Search
Ecamsule
go.drugbank.com/drugs/DB09534ApprovedEcamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability.
Mixtures: /enf., Anthelios XL Melt-IN CreamCategories: Compounds used in a research, industrial, or household settingSucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalIt is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … , peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655].
Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm
Depulfavirine
go.drugbank.com/drugs/DB18890InvestigationalDepulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).
Synonyms: 2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide, Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-Streptococcus pneumoniae type 18c capsular polysaccharide antigen
go.drugbank.com/drugs/DB10335ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaMeclofenamic acid
go.drugbank.com/drugs/DB00939ApprovedInvestigationalVet approvedA non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Synonyms: N-(2,6-dichloro-m-tolyl)anthranilic acid, N-(2,6-dichloro-3-methylphenyl)anthranilic acidCategories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticLecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.
Hydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedFDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy … Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.[L46118] The U.S.
Synonyms: 17alpha-Caproyloxypregn-4-ene-3,20-dioneGadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigationalGadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … The product label includes a black box warning regarding the increased risk for NSF among patients with impaired elimination of the drugs.[L43817]